

Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.
You can purchase shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) through any online brokerage.
Other companies in Amylyx Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Amylyx Pharmaceuticals has a consensus price target of $28.67.
The stock price for Amylyx Pharmaceuticals (NASDAQ: AMLX) is $30 last updated November 13, 2026 at 6:11 PM EST.
There are no upcoming dividends for Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and...